Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen plus background inclisiran in ASCVD with elevated lipoprotein(a)
NL-OMON59464Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, hyperlipoproteinemia and hypercholesterolemia comparing Pelacarsen + background inclisiran with Placebo + background inclisiran (2 arms). Primary endpoint: Change in log-transformed lipoprotein(a) concentration from baseline at Month 6. Started Mar 2026; status: completed.
02
Drugs
pelacarsen
03
Conditions
atherosclerotic diseasehyperlipoproteinemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON59464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59464.